Literature DB >> 31531888

Upregulation of GRIM-19 augments the sensitivity of prostate cancer cells to docetaxel by targeting Rad23b.

Haili Lin1,2, Zaixiong Shen1, Hongjie Liu1, Minggen Yang1, Jiangui Lin1, Liutao Luo1, Linyong Liu3, Hong Chen4.   

Abstract

The gene associated with retinoid-interferon mortality (GRIM-19) has been reported to be correlated with drug resistance, whereas its functional role in prostate cancer (PC) is not fully understood. This study aims to clarify the potential role and molecular mechanisms of GRIM-19 on the response of PC cells to chemical drug docetaxel. mRNA and protein level of GRIM-19 expression in cells and tissues of PC were measured by quantitative real-time PCR and western blot, respectively. Knock-down of GRIM-19 in PC cells was performed using siRNA. Cell apoptosis was determined by flow cytometric analysis. DNA damage in PC cells was detected by γ-H2AX staining. GRIM-19 was downregulated in PC tissues and cell lines. Knock-down of GRIM-19 increased the resistance of PC cells to docetaxel, and overexpression of GRIM-19 promoted docetaxel-induced apoptotic death in PC cells. Mechanistically, GRIM-19 downregulated the expression of the survival gene Rad23b, which promoted DNA damage repair. Overexpression of Rad23b reversed GRIM-19-mediated response to docetaxel in PC cells. GRIM-19 promoted the sensitivity of PC cells to docetaxel by downregulating Rad23b, which may serve as a promising target to develop a better strategy of chemotherapy for PC.
© 2019 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  GRIM-19; Rad23b; docetaxel; prostate cancer; sensitivity

Mesh:

Substances:

Year:  2019        PMID: 31531888     DOI: 10.1111/1440-1681.13179

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  1 in total

1.  Deubiquitinase PSMD7 promotes the proliferation, invasion, and cisplatin resistance of gastric cancer cells by stabilizing RAD23B.

Authors:  Jianjiang Wang; Runkun Liu; Huanye Mo; Xuelian Xiao; Qiuran Xu; Wei Zhao
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.